<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495287</url>
  </required_header>
  <id_info>
    <org_study_id>NILG-AML 02/06</org_study_id>
    <nct_id>NCT00495287</nct_id>
  </id_info>
  <brief_title>A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Italy Leukemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northern Italy Leukemia Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was set up to assess:

        1. Standard-dose versus high-dose remission induction therapy. A standard ICE chemotherapy
           vs sequential high-dose cytarabine, with appropriate supportive/prophylactic measures,
           followed by morphological, cytogenetic and molecular monitoring of remission.

        2. A risk-oriented postremission therapy: HR patients will be electively submitted to
           allogeneic stem cell transplantation (allo-SCT), whenever possible (related/unrelated
           donor/cord blood; ablative/non-ablative conditioning according to national and local
           protocols and guidelines). Provided sufficient blood stem cells were previously
           collected (&gt;2x10e6/kg Cluster of Differentiation 34 cells), SR patients and HR patients
           excluded from allo-SCT and aged 65 years or less will be randomized to: myeloablative
           autologous blood stem cell transplantation vs non-myeloablative, multicycle, autologous
           blood stem cell-supported high-dose cytarabine-based therapy.

             -  HR/SR patients unable to be randomized because of inadequate blood stem cell yield
                will receive intermediate-dose consolidation; patients aged &gt;65 years will be
                treated with age-adapted therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult AML is a difficult-to-treat illness because of both biological and therapeutic reasons.
      Most patients are aged &gt;50 years and/or present with comorbid conditions and/or display
      high-risk AML-related features (poor risk, cytogenetics, prior myelodysplasia, secondary
      AML). This results in unsatisfactory response to conventional first-line therapy and makes it
      difficult to apply the most effective post-remission consolidation options (allo-SCT in
      younger patients with HR features, autologous blood stem cell transplantation and high-dose
      cytarabine-based therapy in the remainder).

      In a prior, phase II uncontrolled NILG trial (registered NCT 00400637),a two-step increasing
      intensity induction was adopted in order to optimize induction results. 51% of ICE-refractory
      cases responded to the salvage regimen, irrespective of risk class. In the same study, all HR
      patients had to be sent to allografting whereas SR patients (by clinico-cytogenetics
      criteria) were to receive up to three high-dose cytarabine-based cycles, each one supported
      by a fixed amount of autologous blood-stem cells (1-2x10e6/kg Cluster of Differentiation 34
      cells cells), to minimize the risks of high-dose cytarabine-related myelosuppression and to
      increase treatment intensity by reducing intercycle delays. DFS was 41% at 5 years, 58% in SR
      patients aged &lt;55 years, 47% in SR patients aged &gt;55 years, and 47% in HR patients with an
      identifiable donor. No treatment-related death occurred during the pancytopenic phase in 118
      patients receiving 299 blood stem-cell supported high-dose cytarabine cycles.

      These facts led to the present trial, in which 1) high-dose induction formerly used as
      salvage is directly compared to standard ICE chemotherapy and 2) the blood-stem cell
      supported multicycle high-dose cytarabine program is directly compared to a standard
      autologous blood stem cell transplantation.

      RANDOM 1 CYCLE 1

        -  Standard ICE (all drugs by IV route): idarubicin 12 mg/m2/d on dd 1-3, cytarabine 100
           mg/m2/bd on dd 1-7, etoposide 100 mg/m2/d on dd 1-5, G-CSF from d 11.

        -  High-dose sequential (all drugs by IV route): cytarabine 2* g/m2/bd on dd 1-2 and 8-9,
           idarubicin 18 mg/m2/d on dd 3 and 10, G-Colony Stimulating Factory (G-CSF) from d 11. *1
           g/m2 in frail patients aged 60-65 and in all those aged &gt;65 years.

      CYCLE 2 (if CR achieved after cycle 1): Standard IC: idarubicin 10 mg/m2/d on dd 1-3,
      cytarabine 100 mg/m2/bd on dd 1-7, G-CSF.

      CYCLE 3: Intermediate-dose cytarabine 1 g/m2/bd on dd 1-4 followed by G-CSF and by stem cell
      collection (1-2x10e6/kg CD34+ cells in three separate bags)

      ALLO-SCT (Allogeneic Stem Cells Transplantation): All HR patients are eligible to allo-SCT as
      first therapeutic option. Allo-SCT procedure: any type according to local
      protocols/guidelines.

      RANDOM 2

      All SR patients and HR ones excluded from allo-SCT:

        -  Autologous blood stem cell transplantation after BU-CY2 regimen (Busulfan 0.8 mg/kg IV
           on dd -8 to -5, Cy 60 mg/kg/d on dd -4 to -3, autograft on d 0 (2-6x10e6/kg CD34+ cells)
           and G-CSF from d +1.

        -  Autologous blood stem cell supported multicycle therapy (x3, monthly) with cytarabine 2
           g/m2/bd on dd 1-5, idarubicin 8 mg/m2/d on dd 1-2, autograft on d 6 (1-2x10e6/kg CD34+
           cells) and G-CSF from d 8.

      Patients excluded from Random 2 as well as from allo-SCT receive attenuated, unsupported
      consolidation with 1-2 intermediate-dose cytarabine cycles. Patients aged &gt;65 years are
      excluded from Random 2.

      RISK CLASSIFICATION Cytogenetic risk classification is based on MRC/ECOG-SWOG/CALGB criteria
      (cytogenetic risk classes: favorable, normal/intermediate, unfavorable, other, unknown);
      clinical risk classification is based on selected diagnostic criteria and response to
      chemotherapy cycle 1. The final risk model integrates cytogenetic and clinical risk to
      encompass two broad risk classes (SR and HR).

        -  Standard risk (SR): favorable cytogenetics, CR achieved after cycle 1; or
           normal/intermediate cytogenetics, CR achieved after cycle 1, lack of high-risk
           characteristics.

        -  High risk (HR): unfavorable cytogenetics; or normal/intermediate cytogenetics with any
           high-risk characteristic (WBC &gt;50x10e9/l,FAB M0,6,7 or corresponding WHO, secondary AML,
           Myelodysplastic Syndrome (MDS)-associated AML, hepatosplenomegaly, FLT3 mutation, CR)
           not achieved with cycle, persistent cytogenetic abnormality at CR), or other/unknown
           cytogenetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission induction (R1): Complete remission (CR) rate after cycle 1</measure>
    <time_frame>30 days after beginning chemotherapy.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission consolidation (R2): Length of remission (DFS, disease-free survival)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R1: CR with incomplete hematological recovery</measure>
    <time_frame>30 days after beginning chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R1:Complete cytogenetic remission</measure>
    <time_frame>30 days after beginning chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R1: Treatment-related death (TRD)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R2: Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration and cumulative incidence of relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">573</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remission induction arm A is with conventional chemotherapy cycle (&quot;ICE&quot;: idarubicin, standard-dose cytarabine, etoposide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytosine arabinoside</intervention_name>
    <description>Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.
Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Aracytin</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (Random 1):

          -  Age 16+ years

          -  Diagnosis of untreated (or only hydroxyurea/cyclophosphamide) acute myelogenous
             leukemia (AML, including myeloid sarcoma) or high-risk myelodysplasia (RAEB-2), either
             de novo or following an antecedent hematological disorder, or secondary to
             chemo-radiotherapy for other cancer

          -  Signed informed consent

          -  Adequate sampling for full cytological, cytochemical, cytogenetic and immunobiological
             disease characterization by revised FAB, EGIL and WHO criteria

          -  ECOG performance status 0-2 or reversible ECOG 3 score following intensive care of
             complications.

        Exclusion criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  Pre-existing, uncontrolled pathology such as cardiac disease (congestive/ischemic,
             acute myocardial infarction within the past 3 months, untreatable arrythmias, NYHA
             classes III and IV), severe liver disease with serum bilirubin &gt;3 mg/dL and/or ALT &gt;3
             x upper normal limit (unless attributable to AML), kidney function impairment with
             serum creatinine &gt;2 mg/dL (unless attributable to AML), and severe neuropsychiatric
             disorder that impairs the patient's ability to understand and sign the informed
             consent, or to cope with the intended treatment plan

          -  Known HIV positive serology

          -  Other active hematological or non-hematological cancers with life expectancy &lt;1 year

          -  Pregnancy (fertile women will be advised not to become pregnant while on treatment;
             and male patients to adopt contraceptive methods)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norther Italy Leukemia Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Ematologia Azienda Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>Bz</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Azienda Ospedaliera S.Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Centro TMO - Fondazione IRCSS Ospedale Maggiore</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e TMO - Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - TMO - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U San Giovanni Battista-Divisione Ematologica dell'Universit√†</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 2 - Osp. Molinette San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo di Varese</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern Italy Leukemia Group</investigator_affiliation>
    <investigator_full_name>DR RENATO BASSAN</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Adult patients</keyword>
  <keyword>Cytogenetic risk class</keyword>
  <keyword>Clinico-cytogenetic risk model</keyword>
  <keyword>Risk-oriented therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

